{"id":"NCT00440557","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease","officialTitle":"A Randomized, Open Label, Multicenter Study of Epoetin Alfa Comparing Two Extended-Dosing Regimens, Once-Weekly and Every-Two-Weeks, With the Three-Times-Weekly Dosing Regimen for Initiation and Maintenance Treatment in Anemic Subjects With Chronic Kidney Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2008-02","completion":"2008-02","firstPosted":"2007-02-27","resultsPosted":"2010-02-08","lastUpdate":"2014-05-07"},"enrollment":375,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Epoetin alfa 3 times weekly /once weekly","otherNames":["PROCRIT"]},{"type":"DRUG","name":"Epoetin alfa once weekly","otherNames":["PROCRIT"]},{"type":"DRUG","name":"Epoetin alfa once every two weeks","otherNames":["PROCRIT"]}],"arms":[{"label":"TIW: Epoetin alfa 3 injections Weekly/Once Weekly","type":"EXPERIMENTAL"},{"label":"QW: Epoetin alfa once weekly","type":"EXPERIMENTAL"},{"label":"Q2W: Epoetin alfa once every two weeks","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to demonstrate that once weekly and once every-2-weeks treatment with epoetin alfa, in patients with anemia associated with chronic kidney disease, is not less effective than the approved treatment with epoetin alfa that is given 3 times weekly with respect to changes in hemoglobin.","primaryOutcome":{"measure":"Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22","timeFrame":"From baseline through Week 22","effectByArm":[{"arm":"Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)","deltaMin":1.81,"sd":0.91},{"arm":"Epoetin Alfa:Once Weekly (QW)","deltaMin":1.59,"sd":0.997},{"arm":"Epoetin Alfa:Once Every Two Weeks (Q2W)","deltaMin":1.27,"sd":0.906}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":62,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["19808215"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=32&filename=CR010411_CSR.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":123},"commonTop":["Hypertension","Hyperkalaemia","Urinary tract infection","Diarrhoea","Dizziness"]}}